# A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

> **NCT02611492** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 265 (estimated)

## Conditions studied

- Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Nilotinib
- **DRUG:** Methotrexate
- **DRUG:** Aracytine (Ara C)
- **DRUG:** Granulocyte Colony-Stimulating Factor (G-CSF)
- **DRUG:** Depomedrol
- **DRUG:** Dexamethasone
- **DRUG:** Vincristine
- **DRUG:** Imatinib
- **DRUG:** 6 Mercaptopurine (6MP)

## Key facts

- **NCT ID:** NCT02611492
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2020-12
- **Final completion:** 2025-12
- **Target enrollment:** 265 (ESTIMATED)
- **Last updated:** 2019-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611492, "A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02611492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*